Bio-Techne (TECH) revenue and earnings history
Bio-Techne reported revenue of $1.22B for fiscal 2026 (year ended Jun 30, 2026), −0.4% on the year before.
Over 17 years, from fiscal 2009 to fiscal 2026, revenue grew at a compound rate of +9.4% a year.
Revenue and net income, 18 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026ended Jun 30, 2026 | $1.22B−0.4% | $252M | — | $292M | $28.9M | $263M | $41.4M | $41.7M | $49.9M | $265M | $200M | 10-K |
| 2025ended Jun 30, 2025 |
The latest quarter, insider trades and fund moves: Bio-Techne (TECH) on OQRO.
Common questions
What was Bio-Techne's revenue in fiscal 2026?
$1.22B for the year ended Jun 30, 2026, as reported in its 10-K filed Aug 24, 2026. That is −0.4% on fiscal 2025 ($1.22B).
How fast has Bio-Techne's revenue grown?
From $264M in fiscal 2009 to $1.22B in fiscal 2026: a compound annual growth rate of +9.4% over 17 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Bio-Techne tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
